| Literature DB >> 35563744 |
Gael Galli1,2,3, Pierre Vacher4, Bernhard Ryffel5, Patrick Blanco1,2,3, Patrick Legembre6.
Abstract
Study of the initial steps of the CD95-mediated signaling pathways is a field of intense research and a long list of actors has been described in the literature. Nonetheless, the dynamism of protein-protein interactions (PPIs) occurring in the presence or absence of its natural ligand, CD95L, and the cellular distribution where these PPIs take place render it difficult to predict what will be the cellular outcome associated with the receptor engagement. Accordingly, CD95 stimulation can trigger apoptosis, necroptosis, pyroptosis, or pro-inflammatory signaling pathways such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and phosphatidylinositol-3-kinase (PI3K). Recent data suggest that CD95 can also activate pattern recognition receptors (PRRs) known to sense damage-associated molecular patterns (DAMPs) such as DNA debris and dead cells. This activation might contribute to the pro-inflammatory role of CD95 and favor cancer development or severity of chronic inflammatory and auto-immune disorders. Herein, we discuss some of the molecular links that might connect the CD95 signaling to DAMP sensors.Entities:
Keywords: CD95; apoptosis; auto-immunity; inflammasome; necroptosis; pyroptosis; sting
Mesh:
Substances:
Year: 2022 PMID: 35563744 PMCID: PMC9105874 DOI: 10.3390/cells11091438
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 7.666
Auto-immune lymphoproliferative syndrome (ALPS) classification.
| ALPS Type | Mutation Type |
|---|---|
| ALPS-FAS | CD95 germline homo- or heterozygous mutation |
| ALPS-sFAS | CD95 somatic mutation |
| ALPS-FASLG | CD95L germline mutation |
| ALPS-CASP10 | Caspase 10 germline mutations |
| ALPS-U | ALPS phenotype with no known-ALPS mutation |
DAMP-sensor-associated genetic disorders.
| DAMP-Sensor Mutation | Mutation Type | Autoinflammatory Disorder |
|---|---|---|
| NLRP1 | Loss of function | NAIAD |
| NLRP3 | Gain of function | CAPS = NOMID, FCAS, MWS |
| NLRC4 | Gain of function | SCAN4, MAS |
| Pyrin | Gain of function of MEFV or loss of function of MVK | FMF, HIDS, PAAND |
| PSTPIP1 | Loss of function | PAPA |
CAPS: Cryopyrin-Associated Periodic Syndrome; DAMP: Damage-Associated Molecular Patterns; FCAS: Familial Cold Autoinflammatory Syndrome; FMF: Familial Mediterranean Fever; HIDS: Hyper-IgD Syndrome; MAS: Macrophage Activation Syndrome; MVK: Mevalonate Kinase; MWS: Muckle-Wells Syndrome; NLRP: Nucleotide-binding oligomerization domain, Leucine-rich Repeat and Pyrin domain; NLRC4: NLR Family CARD Domain Containing 4; NOMID: Neonatal-Onset Multisystem Inflammatory Disease; PAAND: Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis; PAPA, Pyogenic sterile Arthritis, Pyoderma gangrenosum, and Acne; PSTPIP1: Proline Serine Threonine Phosphatase-Interacting Protein 1; SCAN4: Syndrome of enterocolitis and Autoinflammation associated with mutation in NLRC4; TNFR1: TNF-Receptor-1; TRAPS: TNF-Receptor-Associated Periodic Syndrome.
Figure 1CD95 stimulation and potential links with inflammasome activation. At least three molecular complexes could occur upon CD95 engagement to trigger either apoptosis (pink circle), inflammation (green circle), or necrosis (blue circle). Apoptotic and necroptotic complexes control each other and the inflammatory complex (red lines). Necroptosis and pyroptosis signaling pathways lead to the break of the plasma membrane. IAPs also control an additional complex and these members are known to participate in the TNF-R-mediated signaling pathway. The NLRP3 inflammasome, which is activated by signal 1 + 2 is depicted. (GsdmD = Gasdermin D).
Figure 2Representation of ion channels involved in the inflammasome activation. Different plasma membrane or endoplasmic reticulum ion channels have been involved in ion fluxes (black arrows) responsible for the signal 2 activating the inflammasome.